SUVEN PHARMACEUTICALS
|
|
BOM : 543064     NSE : SUVENPHAR     | |
LT :  
    Long Term Analysis
Fundamentals : Good
Valuation : Bad [Stock is Expensive] Debt : Low |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Downward Pledged Shares : None or < 25% |
Jan 28,2025 |
Price(EOD): ₹ 976.25
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: ₹ 24,855.33 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
SUVEN PHARMACEUTICALS | -4.6% | -14.5% | 43.7% |
SUN PHARMACEUTICAL INDUSTRIES | -5.1% | -9.4% | 29.2% |
CIPLA | -1.4% | -6.7% | -1.5% |
DR REDDYS LABORATORIES | -9% | -14.4% | 1.4% |
ZYDUS LIFESCIENCES | -7% | -5% | 22.6% |
DIVIS LABORATORIES | -7.3% | -10.9% | 53% |
MANKIND PHARMA | -2.2% | -13.9% | 19.3% |
TORRENT PHARMACEUTICALS | 4.7% | -1.7% | 32.9% |
LUPIN | -5.4% | -12.4% | 43.4% |
FUNDAMENTAL ANALYSIS OF SUVEN PHARMACEUTICALS
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF SUVEN PHARMACEUTICALS
 Ratio | Consolidated | |
---|---|---|
P/E P/B P/S |
102.32
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 242.88 Cr
[Latest Qtr - Sep2024 - Consolidated Results ] 12.13
P/B Calculated based on Book Value of Rs 2,048.67 Cr
[Latest Year - Mar2024 - Consolidated Results ] 25.86
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 961.16 Cr
[Latest Qtr - Sep2024 - Consolidated Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
334% 329% 330% |
SHARE PRICE MOMENTUM OF SUVEN PHARMACEUTICALS
SUVEN PHARMACEUTICALS vs SENSEX
DEBT OF SUVEN PHARMACEUTICALS
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2024 2023 2022 Avg_3yrs |
0.02 0.04 0.06 0.04 |
0.02 0.04 0.06 0.04 |
[Last Annual Data : Mar2024]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF SUVEN PHARMACEUTICALS
Pledged Promoter Shares |
0 % | |
---|---|---|
As on : Dec2023 | ||
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF SUVEN PHARMACEUTICALS
Consolidated | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
11.72% 30.13% 19.75% 34.9% |
11.54% 5.44% -5.59% 3.05% |
QtrlyTrend |
6 | |
Latest Qtr: Sep2024 | ||
Quarterly Result Analysis → |
SUVEN PHARMACEUTICALS related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
S&P BSE ALLCAP | -0.3% | -3.5% | 35.8% |
S&P BSE 500 | -2.3% | -6.7% | 8.4% |
S&P BSE HEALTHCARE | -5.4% | -9.8% | 22% |
S&P BSE 400 MIDSMALLCAP | -5.6% | -11.5% | 9.4% |
S&P BSE MIDSMALLCAP | -7.1% | -11.2% | 8.4% |
NSE Indices | 1W | 1M | 1Y |
---|---|---|---|
NIFTY 500 | -2.4% | -6.8% | 9% |
NIFTY500 MULTICAP 50:25:25 | -3.6% | -8.5% | 9% |
NIFTY MID SMALL400 | -5.9% | -11.5% | 9.1% |
NIFTY SMALLCAP250 | -8.2% | -14.6% | 6.5% |
You may also like the below Video Courses
FAQ about SUVEN PHARMACEUTICALS
Is SUVEN PHARMACEUTICALS good for long term investment?
As on Jan 28,2025, the Fundamentals of SUVEN PHARMACEUTICALS look Strong and hence it may be good for long term investment! See Financial Performance of SUVEN PHARMACEUTICALS . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is SUVEN PHARMACEUTICALS UnderValued or OverValued?
As on Jan 28,2025, SUVEN PHARMACEUTICALS is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of SUVEN PHARMACEUTICALS ?
As on Jan 28,2025, the Intrinsic Value of SUVEN PHARMACEUTICALS is Rs. 227.13 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 225.14
Fair Value [Median EV / Sales Model] : Rs. 227.44
Fair Value [Median Price / Sales Model] : Rs. 227.13
Estimated Median Fair Value of SUVEN PHARMACEUTICALS : Rs. 227.13
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.